healthcapital

biotech investments & advisory worldwide

Biotech Concerto #3 *European Clinical Trial Environment*

December 2008



- EU Directive
- EU Approval System
- European Authority: EMEA
- The Guidance Documents
- Route Map
- Challenges
- EMEA Organization Chart
- Stakeholders

OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001

on the approximation of the laws,

regulations, and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use

12UH DE Official Journal of the Tarrepoint Communities 1.520			1.5200	
DEDUCTIVE DODADO OF THE DESCRIPTION		DAENT AND OF THE COUNCIL		
	+1 2000			
on the approximation of the laws, segmention on adopting to the implementation of good clinic medicing production	d provis	is in the conduct of dissical trials we		
THE DEBORDAN PARAMETER AND THE COUNCIL OF THE DEBORDAN LINEAR.	19	Persons who are incapable of giving logi- dinical mide deaded by given special per- image in the Mender States in Leg-	action, it is	
Haring regard to the Thony stablishing the Taropean Community, and in particular Article 95 theoret.		this effect, Such percose may use he induited in deficid with it for heavier results are the detailed using persons equilible of giving remners. Neverthis these persons detailed be unleaden at channel when class are ground. For expecting that the administering of the treational product would be of direct bundle to the partial, theory outworkplay for this. Inverse, there is a the partial, theory outworkplay for this. Inverse, there is		
Here, a regard to the proposal flow the thermal scale $\ell_{\rm S}$				
turing regard to the spinon of the tecnomic and total total total total total and the		a need for charact units constrainty children to improve the unconnect available to fram. Children approach a vulnerable propulsion with developmental, physiological and psychological differences (from addite, which rindle-		
Acong a accordance with the providers had down as a rank-201 of the Tasaty $\dot{f}_{\rm D}$		age, and development, related nearth a their benefit, blacking products, including children merch to be spiral scientifically optical ass. The cash could be admired by mediatual products which are likely to be-	ractors for inter wide- dowing that	
evisions 10 Control Direction 9(1)(1)(2)) of 26 January 1995 on the approximation of provisions hild down by law, regulation or administrative anisor relating to architecture to place a resultion production to the surface (head by accompanie) by a downlow remaining particular, and		their spin of the bar on the provident of the spin of	erried out	
documents relating to the testle of insta and chiral relat-carried out on the product. Coursel Disactive 7.9, 104/02; of 20 May 1973 on the approximation of the laws of thumber these relating or anipprint plantame- ronicological and chiral standards and protocols in respect of the testing of molalized protocol (higo down mellions relation on the compliation of docting inducing their presentation).		In the case of other prevents tampaide of containt, such as persons with dimensio- gatings, e.e., inclusion in clinical ratio is denied by our air even more remarking bo- products only when these are greateds for - videals scale when these are greateds for - dee dates benefits on the pairses rearreng Monorrest, in each cases the version of	 psychianic r such cases is the drawn di such such, somning that we for rides 	
14. The accepted basis for the combine of clusted ratio to bounds a fourished in the protection of human rights and the digative of the bounds being with regard to the application of biology and marking, as for instance reduced in the providement of the bounds in the Lamann. The cluster is related basis of the lamann. The cluster with relation's protection is suffigurable through relations are also been as the results of markets.		paratra lagi representativa, gradi ti con the transiti decot, is necessary before pa any such classic with		
legical experiments prior to any situated total, screening by other computations and residence to our component	6	The motion of legal representative roles by		
activities, and rates of the provident of personal data activities, and rates of the personal data of the persona		oses only	e constal of	
[10] C. M. B. LIVER, p. L. Optimies of the Databaset Prefactions of 17 Decard Inter Prefaction of 20 July 2005 (2) 1. 1098, p. 27; Classical Commun Frankiss of 20 July 2005 (2) 1. 1098, 2018 (2019), 25 and Database of the Interplain Prefactions, of 12 Decard Databaset Decard Databaset of 15 Information Commun. 2018 (2019), 2019. Control Databaset of 15 Information Prefactions, of 12 Decard Databaset Databaset Databaset of 15 Information Prefactions, of 12 Decard Databaset Databaset Databaset of 15 Information Prefactions, 2019. Control Databaset Databaset of 15 Information Prefactions, 2019. Control Databaset Databa				
1003. 14 OK 22, 0.21190, p. 3100 Brought on last separated by Council Disaster 2014000 (doi:10.1044). Solid 2014. J. 201 (1) OK 1400, 0.01197 (p. 1. Disaster on last senseside by Counciloise		In order to achieve optimizing protection of loss or appendive spectra will not be carried- within the Cornar on ignor in third conservice constant, of or the optimized optimization of the second optimized optimization.	Sec. whether The largest.	

EU Approval System (as of May 1, 2004)

- 27 national approaches with a common minimal basis
 - defined in Directives and Guidelines
 - but implemented in national law, ordinances, decrees of costs, etc. at different times



• The approval remains a national issue, even if the application has been submitted in all European countries in parallel

Source: Hartmut Krafft, PEI, CTFG

healthcapital



The European Medicines Agency (EMEA) is a decentralized body of the European Union with headquarters in London. It is responsible for the scientific evaluation of applications for European marketing authorization for medicinal products (centralized procedure).

All medicinal products for human and animal use derived from biotechnology and other high technology processes must be approved via the centralized procedure. The same applies to all human medicines intended for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions, and viral diseases, as well as to all designated orphan medicines intended for the treatment of rare diseases.

The safety of medicines is monitored constantly by the Agency through a pharmacovigilance network. The EMEA takes appropriate actions if adverse drug reaction reports suggest changes to the benefit/ risk balance of a medicinal product.

Source: EMEA

Institutional Review Boards (IRBs) are also known as an independent ethics committee or ethical review board.

- The Ethics Committee, according to Directive 2001/20/EC, is an independent body in a Member State of the European Union, consisting of healthcare professionals and nonmedical members, whose responsibility it is to protect the rights, safety and well being of human subjects involved in a clinical trial and to provide public assurance of that protection, by, among other things, expressing an opinion on the clinical trial protocol, the suitability of the investigators involved in the trial and the adequacy of facilities, and on the methods and documents to be used to inform trial subjects and obtain their informed consent.
- With the Clinical Trials Directive, the European Union (EU) envisioned a harmonization of research ethics committees (RECs) across Europe, including the time taken to assess a trial proposal and the kinds of issues a committee should take into account.

Source: Wikipedia

- Detailed Guidelines on the principles of good clinical practice in the conduct in the EU of clinical trials on medicinal products for human use
- Detailed guidance on the application format and documentation to be submitted inan application for an ethics committee opinion on a clinical trial on a medicinalproduct for human use
- Detailed guidance for the request for authorization of a clinical trial on a medicinalproduct for human use to the competent authorities in the European Union, notification of substantial amendments and declaration of the end of a clinical trial
- Detailed guidelines on the trial master file and archiving to implement the directive on Clinical Trials on medicinal products for human use
- Detailed guidance on the collection, verification and presentation of adversereaction reports arising from clinical trials on medicinal products for human use
- Detailed guidance on the European database of Suspected Unexpected SeriousAdverse Reactions (Eudravigilance-Clinical Trial Module)
- Detailed guidance on the European clinical trials database (EUDRACT Database)
- Detailed guidelines on inspection procedures for the verification of GCP compliance to implement the directive on Clinical Trials on medicinal products for human use

Source: Francis P. Crawley, Good Clinical Practice Alliance

biotech investments & advisory

- Detailed guidelines on the qualifications of inspectors who should verify compliancein clinical trials with the provisions of Good Clinical Practice for an investigational medicinal product to implement the directive on Clinical Trials on medicinal products for human use
- Manufacturing and/or Import Authorization of Investigational Products for Human Use-Contents of the Application
- Authorization Referred to in Article 13, Paragraph 1 of Directive 2001/20/EC: Requirements to Obtain Authorization and Requirements to Be Met by the Holder of This Authorization
- Draft Proposal for a Commission Directive.../.../EC Amending 91/356/EEC, Laying Down the Principles and Guidelines of Good Manufacturing Practice for Medicinal Products for Human Use
- Modifications of Commission Directive 91/356/EEC of 13 June 1991 Laying Down the Principles and Guidelines of Good Manufacturing Practice for Medicinal Products for Human Use (*two column informal working document*)
- Volume 4: Good Manufacturing Practices; Annex 13: Manufacture of Investigational Medicinal Products; November 2001


Source: Francis P. Crawley, Good Clinical Practice Alliance

biotech investments & advisory

Route Map (UK Example)

biotech investments & advisory worldwide


Planning a New Clinical Trial



Source: www.ct-toolkit.ac.uk, adapted

Route Map (UK Example)


Trial Management and Closure



biotech investments & advisory worldwide

- Lack of consistency across member states regarding the contents of the 'Clinical Trials Application' (CTA)
- Lack of a consistent definition of an 'Investigational Medicinal Product (IMP)'
- Lack of clarity and consistency regarding the definition of 'substantial amendment'
- Lack of consistent GMP requirements for IMPs across member states
- No mutual recognition procedures between competent authorities
- Inconsistent application formats to ethics committees within and across Member States
- Inconsistent ethical review approaches
- Need for a simplification and harmonization of EU legislation in pharmaceuticals
- Definition of 'non-interventional' clinical trials needs clarification
- SUSAR definition unclear
- Eudravigilance Database not being used or resourced consistently and effectively
- Recommitment to the implementation of the Directive in a harmonized manner

Source: Francis P. Crawley, Good Clinical Practice Alliance



Source: EMEA

- Francis P. Crawley, Executive Director, Good Clinical Practice Alliance (GCPA) Europe
- Prof. Hartmut Krafft, Chairman of the Clinical Trial Facilitation Group (CTFG)
- Georgette Lalis, Director, DG Enterprise and Industry, European Commission
- Thomas Lönngren, Executive Director EMEA
- Fernand Sauer, Director of the Directorate Public Health and Risk Assessment,
- Health & Consumer Protection Directorate General, European Commission

* alphabetical order by last name



Contact

Healthcapital SA Via F. Pelli 2 CH-6900 Lugano / Switzerland Phone: +41-91-911-8415 Fax: +41-91-911-8414 info@healthcapital.ch www.healthcapital.ch Twitter: @healthcapital1